{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:17:21Z","timestamp":1790061441942,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ctrv.2026.103094","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T07:44:30Z","timestamp":1769240670000},"page":"103094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer: A meta-analysis of randomized trials"],"prefix":"10.1016","volume":"144","author":[{"given":"Riccardo","family":"Vida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Montico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Baldassarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Ditto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Zapelloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Rizzetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Lay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poletto","family":"Margherita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2026.103094_b0005","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13048-021-00862-5","article-title":"Efficacy of PD-1\/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis","volume":"14","author":"Zhu","year":"2021","journal-title":"J Ovarian Res"},{"issue":"14","key":"10.1016\/j.ctrv.2026.103094_b0010","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: a systematic review and a meta-analysis","volume":"13","author":"Zeng","year":"2023","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103094_b0015","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103094_b0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103094_b0025","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103094_b0030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103094_b0035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10456-020-09734-w","article-title":"Are antiangiogenics a good \u2018partner\u2019 for immunotherapy in ovarian cancer?","volume":"23","author":"Garc\u00eda-Mart\u00ednez","year":"2020","journal-title":"Angiogenesis"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103094_b0040","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103094_b0045","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified overall Survival Analysis of CLEAR, a phase III Study","volume":"42","author":"Motzer","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103094_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.05.016","article-title":"Lenvatinib Plus Pembrolizumab, Pemetrexed, and a platinum as First-Line Therapy for Metastatic Nonsquamous Non\u2013Small-Cell Lung Cancer: phase 3 LEAP-006 Study","author":"Herbst","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103094_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.05.020","article-title":"LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC that has Progressed after an Anti\u2013PD-(L)1 Plus platinum Chemotherapy","author":"Leighl","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103094_b0060","unstructured":"Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, et al. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. j immunotherapy cancer [Internet]. 2019 Dec [cited 2025 Jul 21];7(1). Available from: https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0489-5."},{"issue":"2","key":"10.1016\/j.ctrv.2026.103094_b0065","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 Immunohistochemistry Assays for Lung Cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103094_b0070","doi-asserted-by":"crossref","unstructured":"Biomarkers for Response to Anti\u2013PD-1\/Anti\u2013PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis. ONCOLOGY. 2023 May 11;(3705):210\u20139.","DOI":"10.46883\/2023.25920995"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103094_b0075","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103094_b0080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103094_b0085","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/jamaoncol.2024.6797","article-title":"Pembrolizumab in patients with Advanced Clear Cell Gynecological Cancer: a phase 2 Nonrandomized Clinical Trial","volume":"11","author":"Kristeleit","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103094_b0090","unstructured":"Gao B, Carlino MS, Michael M, Underhill C, Marshall H, Gunjur A, et al. Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial. JAMA Oncol [Internet]. 2025 Jul 3 [cited 2025 Jul 21]; Available from: https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2835771."},{"key":"10.1016\/j.ctrv.2026.103094_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103550","article-title":"43O durvalumab (D) + carboplatin\/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1\/BRCA2 mutation (non-tBRCAm): Updated results from DUO-O","volume":"9","author":"Trillsch","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103094_b0100","doi-asserted-by":"crossref","first-page":"S1223","DOI":"10.1016\/j.annonc.2024.08.2269","article-title":"LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103094_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101704","article-title":"Chemotherapy with or without Pembrolizumab Followed by Maintenance with Olaparib or Placebo for First-Line Treatment of Advanced BRCA Non-Mutated Epithelial Ovarian Cancer: results from the Randomized phase 3 ENGOT-OV43\/GOG-3036\/KEYLYNK-001 Study","volume":"35","author":"Vergote","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ctrv.2026.103094_b0110","article-title":"Dostarlimab and niraparib in primary advanced ovarian cancer","volume":"S0923753425002017","author":"Hardy-Bessard","year":"2025","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103094_b0115","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103094_b0120","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, Bevacizumab, and Chemotherapy for newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized phase III Trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"JCO"},{"issue":"36","key":"10.1016\/j.ctrv.2026.103094_b0125","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.24.00668","article-title":"Atezolizumab combined with platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 months: ENGOT-OV41\/GEICO 69-O\/ANITA phase III Trial","volume":"42","author":"Gonz\u00e1lez-Mart\u00edn","year":"2024","journal-title":"JCO"},{"issue":"30","key":"10.1016\/j.ctrv.2026.103094_b0130","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1200\/JCO.23.00529","article-title":"Atezolizumab combined with Bevacizumab and Platinum-based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized phase III ATALANTE\/ENGOT-ov29 Trial","volume":"41","author":"Kurtz","year":"2023","journal-title":"JCO"},{"issue":"33","key":"10.1016\/j.ctrv.2026.103094_b0135","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.21.00334","article-title":"Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for patients with Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)","volume":"39","author":"Hamanishi","year":"2021","journal-title":"JCO"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103094_b0140","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:36:05Z","timestamp":1773041765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":28,"alternative-id":["S0305737226000083"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103094","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer: A meta-analysis of randomized trials","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103094"}}